Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2003

View Archived Issues

Phase II findings for onercept in psoriasis and psoriatic arthritis

Peregrine presents antibodies targeting phosphatidylserine

Applied Molecular Evolution to optimize Lilly protein therapeutic candidates

Gilead and Bukwang clevudine licensing agreement terminated

Curis collaboration focusing on Hedgehog signaling pathway

Lorus selects lead antisense compound to target thioredoxin

Inflazyme completes acquisition of GlycoDesign

Y-700 found to inhibit uric acid formation in healthy adult volunteers

SCV-07 stimulates Th1 immune response in TB animal model

Analgesic effects reported for gabapentin in chronic radiculopathy

SMP-114 has good safety profile in healthy volunteers

Durable clinical response found for alefacept plus methotrexate in severe rheumatoid arthritis

Clinical benefits of a human monoclonal antibody against IL-15 in active rheumatoid arthritis

Three series of CCR3 antagonists with utility in asthma therapy claimed by Roche

New GABA-C receptor antagonists and their use as cognition-enhancing agents

Antitumor epothilones identified by Kosan scientists

Pharmacia (Pfizer) team identifies novel pyrazine-based CRF1 antagonists

Apoptosis inducers prepared and tested at the Burnham Institute

Scientists at Fujisawa and Daiso present novel apo B secretion inhibitors

New factor Xa inhibitors and their use covered by Warner-Lambert patent

Idec and Biogen to merge

Enbrel recommended by FDA panel to treat ankylosing spondylitis

Savient chosen as new corporate name for Bio-Technology General

Pilot study of Probuphine initiated for treatment of opiate addiction

MLN-2201 enters phase I testing

CPMP hands down positive opinion for survival claim for MabCampath

European Commission grants marketing authorization for Aldurazyme in Europe

FDA clears IND for dextofisopam for IBS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.